Trial Search Results

Evaluating the Benefits of Physiologic Insulin Delivery

In normal physiology insulin is secreted by beta cells into the portal vein. There have been a number of purported benefits among long-term intraperitoneal insulin users. In the present study we will inject ultra-rapid acting insulin into the upper and lower peritoneum under ultrasound guidance and compare it to subcutaneous injection. We will measure glucose, insulin and glucagon following these injections, to assess for benefits in counter-regulatory hormone production and insulin pharmacokinetics.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institutes of Health (NIH)

Stanford Investigator(s):

Intervention(s):

  • Other: Ultra-rapid insulin

Phase:

N/A

Eligibility


Inclusion Criteria:

   1. 18-60 years of age

   2. Clinical diagnosis of type 1 diabetes

   3. On insulin pump therapy and continuous glucose monitor (CGM) for at least 3 months

   4. Ability to safely receive intraperitoneal injection

   5. For females, not currently known to be pregnant

   6. Understanding and willingness to follow the protocol and sign informed consent

   7. Ability to speak, read and write in the language of the investigators

Exclusion Criteria:

   1. Diabetic ketoacidosis in the past 3 months

   2. Severe hypoglycemia resulting in seizure or loss of consciousness within 3 months
   prior to enrollment

   3. Pregnant or lactating

   4. Active infection

   5. A known medical condition that in the judgment of the investigator might interfere
   with the completion of the protocol

   6. Known cardiovascular events in the last 6 months

   7. Known seizure disorder

   8. Inpatient psychiatric treatment in the past 6 months

   9. Lack of stability on medication 1 month prior to enrollment including
   antihypertensive, thyroid, anti-depressant or lipid lowering medication.

10. Suspected drug or alcohol abuse

11. Chronic kidney disease (GFR < 60 mL/min/1.73m^2)

Ages Eligible for Study

18 Years - 60 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rayhan Lal, MD
650-725-6549
Not Recruiting